FORMULATION OF ANTIGEN AND CPG-ODN WITH COA-ASC16 OPTIMIZES HUMORAL RESPONSE INDEPENDENTLY OF TYPE I INTERFERONS SIGNALING

FEDERICO DANIEL RUIZ MORENO; CONSTANZA MARIN; NICOLAS DANIEL DHO; MERCEDES PASCUAL; ANA CHIODETTI; DANIEL ALLEMANDI; MARÍA C PISTORESI- PALENCIA; GABRIEL MORÓN; SANTIAGO PALMA; BELKYS A. MALETTO

San Miguel de Tucumán

Congreso; LXVII Reunión de la Sociedad Argentina de Inmunología; 2019

Sociedad Argentina de Inmunología

Background: the new vaccines constituted by antigenicsubunits are safe and less expensive, but are not very immunogenic, so theyrequire the incorporation of a vigorous adjuvant. Recently, CpG-ODNwas approved by FDA for a human vaccine. Our vaccine strategy is a nanoformulationwhere the ovalbumin antigen (OVA) and CpG-ODN are formulated with a liquidcrystal bilamellar nanostructure (Coa-ASC16) formed by self-assembly of6-O-ascorbyl palmitate. Previously, we demonstrated that this nanoformulation(OCC) elicited antibodies (IgG1 and IgG2a) and cellular (Th1/Th17 and CD8+ T-cells)responses superior to those induced by a solution of OVA and CpG-ODN (OC) undera three-dose immunization scheme. The CD8+ Tcellresponse induced by OCC was dependent of type I interferons (IFN-I) signaling.Here, we study if the IFN-I pathways have an impact on the antibodies response.Methods: wild-type C57BL/6 and Ifnar1-/- micewere subcutaneously immunized with a single-dose of OCC, OC and OVA and CpG-ODNin solution heated at 80ºC for 15 min and then cooled down to room temperaturein order to simulate the conditions of preparation of the nanostructured formulation(OCø). OVA-specific IgG, IgG2c, and IgG1 titers were evaluated by ELISA.Results: the magnitude and quality of OVA-specific humoral response weresimilar between wild-type and Ifnar1-/- mice. Theimmunization with OCC and OCø induced higher IgG, IgG2c and IgG1 titers than OC(p<0.05) in wild-type and Ifnar1-/- mice. Inconclusion, unlike the CD8+ T cell response,the positive effects on humoral responses induced by Coa-ASC16 were notaffected by the absence of IFN-I signaling. <!-- /* Font Definitions */ @font-face{font-family:Helvetica;panose-1:0 0 0 0 0 0 0 0 0 0;mso-font-alt:Helvetica;mso-font-charset:0;mso-generic-font-family:auto;mso-font-pitch:variable;mso-font-signature:-536870145 1342208091 0 0 415 0;}@font-face{font-family:"Cambria Math";panose-1:2 4 5 3 5 4 6 3 2 4;mso-font-charset:0;mso-generic-font-family:roman;mso-font-pitch:variable;mso-font-signature:-536870145 1107305727 0 0 415 0;}@font-face{font-family:Calibri;panose-1:2 15 5 2 2 2 4 3 2 4;mso-font-alt:Calibri;mso-font-charset:0;mso-generic-font-family:swiss;mso-font-pitch:variable;mso-font-signature:-536859905 -1073697537 9 0 511 0;}@font-face{font-family:"Times New Roman \(Cuerpo en alfa";panose-1:2 11 6 4 2 2 2 2 2 4;mso-font-alt:"Times New Roman";mso-font-charset:0;mso-generic-font-family:roman;mso-font-pitch:variable;mso-font-signature:-536859921 -1073711039 9 0 511 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal{mso-style-unhide:no;mso-style-qformat:yes;mso-style-parent:"";margin:0cm;margin-bottom:.0001pt;mso-pagination:widow-orphan;font-size:12.0pt;font-family:Helvetica;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-bidi-font-family:"Times New Roman \(Cuerpo en alfa";mso-ansi-language:ES-TRAD;mso-fareast-language:EN-US;}.MsoChpDefault{mso-style-type:export-only;mso-default-props:yes;font-family:Helvetica;mso-ascii-font-family:Helvetica;mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-font-family:Helvetica;mso-bidi-font-family:"Times New Roman \(Cuerpo en alfa";mso-ansi-language:ES-TRAD;mso-fareast-language:EN-US;}size:595.0pt 842.0pt;margin:70.85pt 3.0cm 70.85pt 3.0cm;mso-header-margin:35.4pt;mso-footer-margin:35.4pt;mso-paper-source:0;}div.WordSection1{page:WordSection1;}